Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Mandeep Kaur & Marsal Sanches. (2021) Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder. Journal of Experimental Pharmacology 13, pages 181-196.
Read now
Read now
Mani Yavi, Ioline D. Henter, Lawrence T Park & Carlos Zarate. (2021) Key considerations in the pharmacological management of treatment-resistant depression. Expert Opinion on Pharmacotherapy 22:17, pages 2405-2415.
Read now
Read now
Ricardo P. Garay. (2021) Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu. Expert Opinion on Investigational Drugs 30:7, pages 749-758.
Read now
Read now
Michele Fornaro, Andrea Fusco, Annalisa Anastasia, Carlo Ignazio Cattaneo & Domenico De Berardis. (2019) Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy 20:16, pages 1925-1933.
Read now
Read now
Ricardo P. Garay, Thomas Charpeaud, Susan Logan, Patrick Hannaert, Raul G. Garay, Pierre-Michel Llorca & Shefaly Shorey. (2019) Pharmacotherapeutic approaches to treating depression during the perimenopause. Expert Opinion on Pharmacotherapy 20:15, pages 1837-1845.
Read now
Read now
Graham S. Timmins. (2017) Deuterated drugs; updates and obviousness analysis. Expert Opinion on Therapeutic Patents 27:12, pages 1353-1361.
Read now
Read now
Gopalkumar Rakesh, Chi-Un Pae & Prakash S. Masand. (2017) Beyond serotonin: newer antidepressants in the future. Expert Review of Neurotherapeutics 17:8, pages 777-790.
Read now
Read now
Michael Bauer, Emanuel Severus, Hans-Jürgen Möller & Allan H. Young. (2017) Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. International Journal of Psychiatry in Clinical Practice 21:3, pages 166-176.
Read now
Read now
Ricardo P. Garay. (2017) Vaccinating against depression or anxiety: is it plausible?. Expert Opinion on Biological Therapy 17:5, pages 525-528.
Read now
Read now
Articles from other publishers (45)
Xuezhi Ma, Shijie Zhou, Wenyuan Sun, Jie Sun, Guangguang Li, Lining Wang & Yang Guo. (2023) Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 24:1.
Crossref
Crossref
Taís da Silva Teixeira Rech, Dianer Nornberg Strelow, Letícia Devantier Krüger, José Sebastião Santos Neto, Gustavo Bierhals Blödorn, Diego Alves, César Augusto Brüning & Cristiani Folharini Bortolatto. (2023) Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Mujeeb U. Shad. (2023) Recent Developments in Pharmacotherapy of Depression: Bench to Bedside. Journal of Personalized Medicine 13:5, pages 773.
Crossref
Crossref
Il Bin Kim, Seon-Cheol Park & Yong-Ku Kim. 2023. Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders. Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders
209
224
.
John Cook & Angelos Halaris. (2022) Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 119, pages 110603.
Crossref
Crossref
Christopher Armstrong, Julia Ferrante, Nidesh Lamichhane, Zachery Reavis, David Walker, Ashwin Patkar & Cynthia Kuhn. (2022) Rapastinel accelerates loss of withdrawal signs after repeated morphine and blunts relapse to conditioned place preference. Pharmacology Biochemistry and Behavior 221, pages 173485.
Crossref
Crossref
Sheng Yu, Wen Li, Lingxue Tang, Xinxin Fan, Senbang Yao, Xiuqing Zhang, Ziran Bi & Huaidong Cheng. (2022) Depression in breast cancer patients: Immunopathogenesis and immunotherapy. Cancer Letters 536, pages 215648.
Crossref
Crossref
Éva Borbély, Mária Simon, Eberhard Fuchs, Ove Wiborg, Boldizsár Czéh & Zsuzsanna Helyes. (2022) Novel drug developmental strategies for treatment‐resistant depression. British Journal of Pharmacology 179:6, pages 1146-1186.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Vanessa Efinger, Walter E. Müller & Kristina Friedland. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1109
1134
.
Cong-Yuan Xia, Jun He, Li-Da Du, Yu Yan, Wen-Wen Lian, Jie-Kun Xu & Wei-Ku Zhang. (2021) Targeting the dysfunction of glutamate receptors for the development of novel antidepressants. Pharmacology & Therapeutics 226, pages 107875.
Crossref
Crossref
Morgan Lecomte, Mounsef Lahboubi, Pierre Thilmany, Adil El Bouzakhi & Gwilherm Evano. (2021) A general, versatile and divergent synthesis of selectively deuterated amines. Chemical Science 12:33, pages 11157-11165.
Crossref
Crossref
Pavlina Pavlidi, Nikolaos Kokras & Christina Dalla. (2021) Antidepressants’ effects on testosterone and estrogens: What do we know?. European Journal of Pharmacology 899, pages 173998.
Crossref
Crossref
Donald J. AbrahamRichard A. Glennon & Leslie Iversen. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
56
.
G. Schiena, G. Franco, A. Boscutti, G. Delvecchio, E. Maggioni & P. Brambilla. (2021) Connectivity changes in major depressive disorder after rTMS: a review of functional and structural connectivity data. Epidemiology and Psychiatric Sciences 30.
Crossref
Crossref
Michele Fornaro, Domenico De Berardis, Annalisa Anastasia & Andrea Fusco. 2021. Major Depressive Disorder. Major Depressive Disorder
449
461
.
Vanessa Efinger, Walter E. Müller & Kristina Friedland. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
26
.
Ross J. Baldessarini, Gustavo H. Vázquez & Leonardo Tondo. (2020) Bipolar depression: a major unsolved challenge. International Journal of Bipolar Disorders 8:1.
Crossref
Crossref
Michele Protti, Roberto Mandrioli, Camilla Marasca, Andrea Cavalli, Alessandro Serretti & Laura Mercolini. (2020) New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Medicinal Research Reviews 40:5, pages 1794-1832.
Crossref
Crossref
Abdullah Mohammed Ramadan & Islam Ahmed Mansour. (2020) Could ketamine be the answer to treating treatment-resistant major depressive disorder?. General Psychiatry 33:5, pages e100227.
Crossref
Crossref
Peter M. Haddad, David J. Nutt & A. Richard Green. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
1
34
.
Domenico De Berardis, Carmine Tomasetti, Maurizio Pompili, Gianluca Serafini, Federica Vellante, Michele Fornaro, Alessandro Valchera, Giampaolo Perna, Umberto Volpe, Giovanni Martinotti, Silvia Fraticelli, Massimo Di Giannantonio, Yong-Ku Kim & Laura Orsolini. (2020) An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. Current Topics in Medicinal Chemistry 20:7, pages 554-584.
Crossref
Crossref
Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, Carlos A. ZarateJr.Jr. & Siegfried Kasper. (2020) Prognosis and Improved Outcomes in Major Depression: A Review. FOCUS 18:2, pages 220-235.
Crossref
Crossref
Abby Pribish, Nicole Wood & Arun Kalava. (2020) A Review of Nonanesthetic Uses of Ketamine. Anesthesiology Research and Practice 2020, pages 1-15.
Crossref
Crossref
Ross J. Baldessarini, Leonardo Tondo & Gustavo H. Vázquez. 2020. New Directions in Psychiatry. New Directions in Psychiatry
39
82
.
Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, Carlos A. Zarate & Siegfried Kasper. (2019) Prognosis and improved outcomes in major depression: a review. Translational Psychiatry 9:1.
Crossref
Crossref
Lesley J. Scott. (2019) Intranasal esketamine in treatment-resistant depression: a profile of its use. Drugs & Therapy Perspectives 35:11, pages 536-545.
Crossref
Crossref
Li-Hua Cao, Jing-Yi Qiao, Hui-Yuan Huang, Xiao-Yan Fang, Rui Zhang, Ming-San Miao & Xiu-Min Li. (2019) PI3K–AKT Signaling Activation and Icariin: The Potential Effects on the Perimenopausal Depression-Like Rat Model. Molecules 24:20, pages 3700.
Crossref
Crossref
Christoph Kraus, Daniel Wasserman, Ioline D. Henter, Elia Acevedo-Diaz, Bashkim Kadriu & Carlos A. ZarateJr.Jr.. (2019) The influence of ketamine on drug discovery in depression. Drug Discovery Today 24:10, pages 2033-2043.
Crossref
Crossref
Elena Tomaselli Muensterman, Yijia Luo & Jonathon M. Parker. (2019) Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status. Therapeutic Innovation & Regulatory Science, pages 216847901987406.
Crossref
Crossref
Paul J. Fitzgerald & Brendon O. Watson. (2019) In vivo electrophysiological recordings of the effects of antidepressant drugs. Experimental Brain Research 237:7, pages 1593-1614.
Crossref
Crossref
Mariusz Papp, Piotr Gruca, Magdalena Lason, Monika Niemczyk & Paul Willner. (2019) The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression. Journal of Psychopharmacology 33:6, pages 748-756.
Crossref
Crossref
Alex Luedtke, Ekaterina Sadikova & Ronald C. Kessler. (2019) Sample Size Requirements for Multivariate Models to Predict Between-Patient Differences in Best Treatments of Major Depressive Disorder. Clinical Psychological Science 7:3, pages 445-461.
Crossref
Crossref
Yuhao Xu, Hong Wei, Yuanyuan Zhu, Yan Zhu, Ningning Zhang, Jiasheng Qin, Xiaolan Zhu, Ming Yu & Yuefeng Li. (2019) Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression. Journal of Affective Disorders 250, pages 307-312.
Crossref
Crossref
Jeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu & Jodi L. Smith. 2019. Neuropsychotherapeutics. Neuropsychotherapeutics
47
96
.
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Ricardo Garay, Carlos A. ZarateJr.Jr., Icilio Cavero, Yong-Ku Kim, Thomas Charpeaud & Phil Skolnick. (2018) The development of glutamate-based antidepressants is taking longer than expected. Drug Discovery Today 23:10, pages 1689-1692.
Crossref
Crossref
Cheol Lee, Juhwan Lee, Gilho Lee, Hayeong Lee, Zhou Shicheng & Jihyo Hwang. (2018) The effects of a combination of intravenous dexamethasone and ketamine on postoperative mood in patients undergoing laparoscopically assisted-gynecologic surgery. Psychopharmacology 235:8, pages 2417-2422.
Crossref
Crossref
Shan Liang, Xiaoli Wu, Xu Hu, Tao Wang & Feng Jin. (2018) Recognizing Depression from the Microbiota–Gut–Brain Axis. International Journal of Molecular Sciences 19:6, pages 1592.
Crossref
Crossref
Ronald S. Duman. (2018) Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research 7, pages 659.
Crossref
Crossref
Ronald C. Kessler. (2018) The potential of predictive analytics to provide clinical decision support in depression treatment planning. Current Opinion in Psychiatry 31:1, pages 32-39.
Crossref
Crossref
J.R. Sneyd. (2017) Thiopental to desflurane - an anaesthetic journey. Where are we going next?. British Journal of Anaesthesia 119, pages i44-i52.
Crossref
Crossref
Jiyao Sheng, Shui Liu, Yicun Wang, Ranji Cui & Xuewen Zhang. (2017) The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plasticity 2017, pages 1-10.
Crossref
Crossref
Gerd Laux. 2016. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1
107
.
Cynthia Kuhn, Nidesh Lamicchane, Julia Ferrante, Zachery Reavis, Q.D. Walker, A Patkar & Christopher Armstrong. (2022) Rapastinal Accelerates Loss of Withdrawal Signs after Repeated Morphine and Blunts Relapse to Conditioned Place Preference. SSRN Electronic Journal.
Crossref
Crossref